Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
08:30am, Thursday, 15'th May 2025
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therap
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
08:30am, Tuesday, 13'th May 2025
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Milestone Achieved as Adovate Initiates First-in-Human Study fo
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
11:48am, Friday, 02'nd May 2025
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spe
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
08:30am, Tuesday, 04'th Mar 2025
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
09:00am, Tuesday, 25'th Feb 2025
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
09:00am, Wednesday, 12'th Feb 2025
New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence New Patent expands patent estate covering Adial's
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 25'th Nov 2024
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
08:30am, Tuesday, 05'th Nov 2024
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
09:00am, Wednesday, 23'rd Oct 2024
Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
09:00am, Wednesday, 23'rd Oct 2024
GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
08:30am, Thursday, 19'th Sep 2024
GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
